Cargando…
Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice
Despite ongoing vaccination efforts to prevent SARS-CoV-2 infections, treatment tools are still necessary to address the ongoing COVID-19 pandemic. We report here that COVID-HIGIV, a human immunoglobulin product for treatment of COVID-19, provided a significant survival benefit in SARS-CoV-2 infecte...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860936/ https://www.ncbi.nlm.nih.gov/pubmed/36680164 http://dx.doi.org/10.3390/v15010123 |
_version_ | 1784874715862532096 |
---|---|
author | Jha, Aruni Doyle-Eisele, Melanie Revelli, David Carnelley, Trevor Barker, Douglas Kodihalli, Shantha |
author_facet | Jha, Aruni Doyle-Eisele, Melanie Revelli, David Carnelley, Trevor Barker, Douglas Kodihalli, Shantha |
author_sort | Jha, Aruni |
collection | PubMed |
description | Despite ongoing vaccination efforts to prevent SARS-CoV-2 infections, treatment tools are still necessary to address the ongoing COVID-19 pandemic. We report here that COVID-HIGIV, a human immunoglobulin product for treatment of COVID-19, provided a significant survival benefit in SARS-CoV-2 infected transgenic mice compared to controls. COVID-HIGIV also has similar pharmacokinetic profiles in healthy and SARS-CoV-2 infected mice over time after intravenous administration, with identical or comparable Tmax, Cmax, AUC(0–∞) and Cl. AUC(0–last) increased and mean residence time, T(1/2), and Vd reduced in infected animals compared to healthy animals. These data suggest that COVID-HIGIV may be an effective treatment for SARS-CoV-2 infection when given early after exposure. |
format | Online Article Text |
id | pubmed-9860936 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98609362023-01-22 Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice Jha, Aruni Doyle-Eisele, Melanie Revelli, David Carnelley, Trevor Barker, Douglas Kodihalli, Shantha Viruses Communication Despite ongoing vaccination efforts to prevent SARS-CoV-2 infections, treatment tools are still necessary to address the ongoing COVID-19 pandemic. We report here that COVID-HIGIV, a human immunoglobulin product for treatment of COVID-19, provided a significant survival benefit in SARS-CoV-2 infected transgenic mice compared to controls. COVID-HIGIV also has similar pharmacokinetic profiles in healthy and SARS-CoV-2 infected mice over time after intravenous administration, with identical or comparable Tmax, Cmax, AUC(0–∞) and Cl. AUC(0–last) increased and mean residence time, T(1/2), and Vd reduced in infected animals compared to healthy animals. These data suggest that COVID-HIGIV may be an effective treatment for SARS-CoV-2 infection when given early after exposure. MDPI 2022-12-30 /pmc/articles/PMC9860936/ /pubmed/36680164 http://dx.doi.org/10.3390/v15010123 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Jha, Aruni Doyle-Eisele, Melanie Revelli, David Carnelley, Trevor Barker, Douglas Kodihalli, Shantha Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice |
title | Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice |
title_full | Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice |
title_fullStr | Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice |
title_full_unstemmed | Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice |
title_short | Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice |
title_sort | pharmacokinetic and pharmacodynamic effects of polyclonal antibodies against sars-cov2 in mice |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860936/ https://www.ncbi.nlm.nih.gov/pubmed/36680164 http://dx.doi.org/10.3390/v15010123 |
work_keys_str_mv | AT jhaaruni pharmacokineticandpharmacodynamiceffectsofpolyclonalantibodiesagainstsarscov2inmice AT doyleeiselemelanie pharmacokineticandpharmacodynamiceffectsofpolyclonalantibodiesagainstsarscov2inmice AT revellidavid pharmacokineticandpharmacodynamiceffectsofpolyclonalantibodiesagainstsarscov2inmice AT carnelleytrevor pharmacokineticandpharmacodynamiceffectsofpolyclonalantibodiesagainstsarscov2inmice AT barkerdouglas pharmacokineticandpharmacodynamiceffectsofpolyclonalantibodiesagainstsarscov2inmice AT kodihallishantha pharmacokineticandpharmacodynamiceffectsofpolyclonalantibodiesagainstsarscov2inmice |